Wednesday, August 07, 2019 Three new publications from the CCTG Committee on Economic Analysis Can Administrative Data Improve the Performance of Cancer Clinical Trial Economic Analyses? Hanna TP, Nguyen P, Pater J, O'Callaghan CJ, Mittmann N, Earle CC, Tu D, Jonker D, Hay AE. J Oncol Pract. 2019 Jul 15:JOP1800691. doi: 10.1200/JOP.18.00691. [Epub ahead of print] The economic impact of the transition from branded to generic oncology drugs. Cheung WY, Kornelsen EA, Mittmann N, Leighl NB, Cheung M, Chan KK, Bradbury PA, Ng RCH, Chen BE, Ding K, Pater JL, Tu D, Hay AE. CAR T-cells: costs, comparisons, and commentary. Hay AE, Cheung MC. J Med Econ. 2019 Jul;22(7):613-615. doi: 10.1080/13696998.2019.1582059. Epub 2019 Mar 21.
